BioSpace News Archive

Dyno will be responsible for the design of the novel AAV capsids that are expected to have improved functional properties for gene therapy. Roche and its subsidiary Spark Therapeutics will take the capsids and conduct preclinical studies with hopes of taking them into the clinic, and eventually to commercialization.

Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the Tokyo-based pharmaceutical company in moving 80% of its applications to the “cloud” and modernizing the company’s research tools.

In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the course of disease1

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.

Guadecitabine did not meet the primary endpoint of improvement in overall survival versus comparator in either study Evaluating options for the future of the guadecitabine program PLEASANTON, Calif. & TOKYO--( BUSINESS WIRE )-- Astex Pharmaceuticals, Inc., a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co., Ltd., today announce top-line results of the ASTRAL-2 and ASTRAL-3 clinical studies that evaluated the effic

Innovent Biologics, Inc. announces the appointment of Dr. Yong Jun Liu, a renowned world class scientist and successful leader in biopharmaceutical industry, as the president of the group.

Accelerate Rx +® business by acquiring innovative technology for ultra-small implantable medical devices and world-class talent in the bioelectronics field

Through June 2021 , the Institute of Medicine of Chicago (IOMC) will host over 15 interactive virtual learning sessions during the “State of Health of Chicago 2020-2021 (SOHOC).” In its 105th year, IOMC announces th

FEP Blue Focus® premiums remain unchanged for third consecutive year, while the program introduces changes across all products to expand access to care [14-October-2020] WASHINGTON , Oct. 14, 2020 /PRNewswire/ -- Today, the Blue Cross® and Blue Shield® Federal Employee Program ® (FEP ® ) announced 2021 benefits, including newly expanded telemedicine benefits, along w

Mallinckrodt plc announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its “First Day” motions related to the Company’ s voluntary Chapter 11 petitions filed on October 12, 2020.